サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429326

抗喘息薬およびCOPD薬の世界市場レポート 2024

Anti-Asthmatics And COPD Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗喘息薬およびCOPD薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

抗喘息薬およびCOPD薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.3%の年間平均成長率（CAGR）で1,041億米ドルに成長すると予想されます。抗喘息薬やCOPD治療薬の成長が期待される背景には、電子タバコの普及、肥満の増加、技術の進歩、未診断人口、COVID-19の治療における薬剤の使用といった要因があります。主な動向としては、喘息治療薬のプロバイオティクス、ポートフォリオ拡大のための抗IL-5薬、革新的な製品の上市、生体電気薬への投資の増加、事業拡大のための共同努力、個別化医療の探求、エアゾール呼吸器治療薬への投資、効果的な医薬品開発のためのバイオマーカー研究、競争のためのジェネリック医薬品への注力、併用薬の開発、生物製剤の生産などが挙げられます。

喫煙、座りっぱなしのライフスタイル、不健康な食生活などの修正可能な危険因子は、抗喘息薬およびCOPD薬市場の推進に大きく貢献しています。世界的に喫煙率が低下している一方で、中国、インド、インドネシア、ナイジェリアなどの特定の発展途上国では喫煙率が上昇傾向にあります。たとえば、インドネシアでは2025年までに喫煙者が2,400万人増加すると予想され、ナイジェリアでは喫煙者が700万人増加すると予想されています。さらに、中国は世界のタバコ消費量の40％以上を占めています。不健康な食事習慣、特に米国や欧州などの高所得国で蔓延している脂肪や飽和脂肪酸の多量摂取は、喘息やCOPDに関連する危険因子の一因となっています。 WHOのデータは、先進国ではエネルギー摂取量の35％以上が脂肪由来であるのに対し、低所得国では20％未満、下位中所得国では25％未満であることを浮き彫りにしています。

喘息性疾患の蔓延は、抗喘息薬およびCOPD薬市場の成長の原動力となると予想されます。気道の炎症と狭窄を特徴とする慢性疾患である喘息は、症例数が増加傾向にあり、これらの疾患を管理するための新しい薬の特定と開発が促されています。たとえば、2022年 4月の国民健康面接調査（NHIS）のデータに基づくと、2020年の米国では18歳以下の子供の約42.7%、5歳未満の子供の約52.9%が喘息を患っていると報告されています。喘息患者の増加は革新的な医薬品の継続的な開発を刺激し、抗喘息薬およびCOPD薬市場をさらに推進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の抗喘息薬およびCOPD薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗ヒスタミン薬
  • 長時間作用型B2アゴニスト（LABA）
  • 吸入コルチコステロイド
  • 短時間作用型ムスカリン受容体拮抗薬（SAMA）
  • その他の抗喘息薬およびCOPD薬（組み合わせを含む）
  • 世界の抗喘息薬およびCOPD薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • プライベートクリニック
  • ドラッグストア
  • 小売薬局
  • eコマース
  • 世界の抗喘息薬およびCOPD薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 喘息患者
  • COPD患者

第7章 地域および国の分析

  • 世界の抗喘息薬およびCOPD薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の抗喘息薬およびCOPD薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 抗喘息薬およびCOPD薬市場の競合情勢
  • 抗喘息薬およびCOPD薬市場の企業プロファイル
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Boehringer Ingelheim GmbH
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG

第31章 その他の大手および革新的な企業

  • Sanofi SA
  • Chiesi Farmaceutici SpA
  • Teva Pharmaceutical Industries Limited
  • Merck &Co. Inc.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • China National Pharmaceutical Group Co. Ltd.（Sinopharm）
  • Shanghai Acebright Pharmaceuticals Group Co. Ltd.
  • Jiangsu Hengrui Medicine Co. Ltd
  • Hanmi Pharmaceutical
  • Cipla Limited
  • Aurobindo Pharma Limited
  • KYORIN Holdings Inc.
  • Nichi-Iko Pharmaceutical Co. Ltd.
  • Otsuka Pharmaceutical Co. Ltd.
  • Daewoong Pharmaceutical Co. Ltd

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14338

Anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs are medications designed to alleviate the frequency of acute attacks in conditions such as asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

The primary classes of drugs in anti-asthmatics and COPD include bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. Bronchodilators stimulate the bronchi and bronchioles, reducing respiratory airway resistance and enhancing lung airflow. Various types of bronchodilators include anti-histamine drugs, long-acting B2-agonists (LABA), inhaled corticosteroids, short-acting muscarinic receptor antagonists (Samas), and other combinations of anti-asthmatics and COPD drugs. These medications are utilized by asthma and COPD patients and are distributed through diverse channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce platforms.

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report are one of a series of new reports from The Business Research Company that provides anti-asthmatics and chronic obstructive pulmonary disease (COPD) market statistics, including anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry global market size, regional shares, competitors with an anti-asthmatics and chronic obstructive pulmonary disease (COPD) market share, detailed anti-asthmatics and chronic obstructive pulmonary disease (COPD) market segments, market trends and opportunities, and any further data you may need to thrive in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry. These anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-asthmatics and copd drugs market size has grown strongly in recent years. It will grow from $76.16 billion in 2023 to $81.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth observed in the historical period in the field of anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs can be attributed to several key factors. These include an increased prevalence of respiratory diseases, a rise in tobacco smoking incidence, global warming implications, a growing geriatric population, emerging markets, innovative methods for drug discovery, and an overall increase in healthcare expenditure. These factors collectively contributed to the expansion of the market, reflecting the heightened focus on respiratory health, evolving treatment methods, and the impact of demographic and environmental factors on respiratory conditions.

The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $104.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. Anticipated growth in anti-asthmatic and COPD drugs is driven by factors such as the popularity of e-cigarettes, rising obesity, technological advancements, undiagnosed populations, and the drugs' use in treating COVID-19. Key trends include probiotic drugs for asthma, anti-IL-5 drugs for portfolio expansion, innovative product launches, increased investments in bioelectric medicines, collaborative efforts for business expansion, exploration of personalized medicine, investment in aerosol respiratory drugs, biomarker research for effective drug development, focus on generic drugs for competition, development of combination drugs, and production of biologics.

Modifiable risk factors such as smoking, sedentary lifestyles, and unhealthy dietary habits significantly contribute to driving the anti-asthmatics and copd drugs market. While smoking rates are declining globally, certain developing nations such as China, India, Indonesia, and Nigeria are witnessing an upward trend in smoking prevalence. For example, Indonesia is anticipated to see a rise of 24 million tobacco smokers by 2025, while Nigeria is expected to witness an increase of 7 million smokers. Additionally, China holds over 40% of global cigarette consumption. Unhealthy dietary practices, especially high consumption of fats and saturated fatty acids prevalent in high-income countries such as the USA and Europe, contribute to the risk factors associated with Asthma and COPD. WHO data highlights that in developed countries, over 35% of energy intake comes from fats, in contrast to less than 20% in low-income countries and below 25% in lower-middle-income countries.

The prevalence of asthmatic disorders is anticipated to be a driving force behind the growth of the anti-asthmatics and COPD drugs market. Asthma, a chronic condition characterized by airway inflammation and constriction, has shown an upward trend in cases, prompting the identification and development of new medications to manage these disorders. For example, based on data from the National Health Interview Survey (NHIS) in April 2022, approximately 42.7% of children aged 18 or younger and 52.9% of children under 5 years old were reported to have asthma in the United States in 2020. This rise in asthmatic cases is expected to stimulate the continuous development of innovative drugs, further propelling the anti-asthmatics and copd drugs market.

Numerous inhalers devoid of chlorofluorocarbons (CFCs) are presently accessible for managing asthma and chronic obstructive pulmonary disease (COPD). While these products might not be formally designated as direct replacements for CFC Metered Dose Inhalers, they can be considered beneficial medications for many patients, potentially eliminating the necessity for specific CFC Metered Dose Inhalers. The determination of official alternatives will be made by the FDA, employing criteria established via notice-and-comment rulemaking processes.

Major players within the anti-asthmatics and COPD drugs market are driving innovation with products such as the dose combination (FDC) drug, Indacaterol plus Mometasone, aiming to enhance their market position. This FDC medication, administered via the Breezhaler device, represents a once-daily treatment designed for ongoing asthma management in patients. Glenmark Pharmaceuticals, for instance, introduced the novel FDC drug named Indamet in India in June 2022. Available in three variations, Indamet maintains a consistent dose of 150 mcg of Indacaterol while varying Mometasone doses (80 mcg, 160 mcg, and 320 mcg strengths) to address uncontrollable asthma cases.

The trend toward combination therapies for asthma and COPD treatment is on the rise, showcasing greater efficacy in patient-reported outcomes (PROs) compared to monotherapies. Combinations such as short-acting beta-agonists (SABA) coupled with short-acting muscarinic antagonists (SAMA) have demonstrated superior effects on lung function when compared to individual medications. Similarly, the utilization of long-acting beta-agonists (LABA) paired with long-acting muscarinic antagonists (LAMA) has shown improved lung function in comparison to long-acting monotherapy bronchodilators.

Major companies operating in the anti-asthmatics and copd drugs market report are GlaxoSmithKline PLC, AstraZeneca PLC, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd., GSK, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd., Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Cipla Medpro South Africa (Pty) Limited, Aspen Nigeria

North America was the largest region in the anti-asthmatics and COPD drugs market in 2023. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and copd drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-asthmatics and copd drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The anti-asthmatic and chronic obstructive pulmonary disease market consists of corticosteroid, bronchodilator, fluticasone and salmeterol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Asthmatics And COPD Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-asthmatics and COPD drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-asthmatics and COPD drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-asthmatics and COPD drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Class: Bronchodilators; Anti-Inflammatory Drugs; Monoclonal Antibodies; Combination Drugs
  • 2) By Distribution Channel: Hospital Pharmacies; General Pharmacies; Online Retailers
  • 3) By End User: Asthma Patients; COPD Patients
  • 4) By Therapy: Preventive; Curative
  • 5) By Route Of Administration: Oral; Inhaled; Intravenous; Subcutaneous
  • 6) By Age Group: Below 5; 5-14; 15-60; Above 60
  • Companies Mentioned: GlaxoSmithKline plc; AstraZeneca plc; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-Asthmatics And COPD Drugs Market Characteristics

3. Anti-Asthmatics And COPD Drugs Market Trends And Strategies

4. Anti-Asthmatics And COPD Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Anti-Asthmatics And COPD Drugs Market Size and Growth

  • 5.1. Global Anti-Asthmatics And COPD Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Anti-Asthmatics And COPD Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Anti-Asthmatics And COPD Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anti-Asthmatics And COPD Drugs Market Segmentation

  • 6.1. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Anti-histamine Drugs
  • long-acting B2-agonists (LABA)
  • Inhaled corticosteroids
  • Short-acting muscarinic receptor antagonists (SAMAs)
  • Other Anti-Asthmatics And COPD Drugs (including Combinations)
  • 6.2. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce
  • 6.3. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Asthma Patients
  • COPD Patients

7. Anti-Asthmatics And COPD Drugs Market Regional And Country Analysis

  • 7.1. Global Anti-Asthmatics And COPD Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Anti-Asthmatics And COPD Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anti-Asthmatics And COPD Drugs Market

  • 8.1. Asia-Pacific Anti-Asthmatics And COPD Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anti-Asthmatics And COPD Drugs Market

  • 9.1. China Anti-Asthmatics And COPD Drugs Market Overview
  • 9.2. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anti-Asthmatics And COPD Drugs Market

  • 10.1. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anti-Asthmatics And COPD Drugs Market

  • 11.1. Japan Anti-Asthmatics And COPD Drugs Market Overview
  • 11.2. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anti-Asthmatics And COPD Drugs Market

  • 12.1. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anti-Asthmatics And COPD Drugs Market

  • 13.1. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anti-Asthmatics And COPD Drugs Market

  • 14.1. South Korea Anti-Asthmatics And COPD Drugs Market Overview
  • 14.2. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anti-Asthmatics And COPD Drugs Market

  • 15.1. Western Europe Anti-Asthmatics And COPD Drugs Market Overview
  • 15.2. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anti-Asthmatics And COPD Drugs Market

  • 16.1. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anti-Asthmatics And COPD Drugs Market

  • 17.1. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anti-Asthmatics And COPD Drugs Market

  • 18.1. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anti-Asthmatics And COPD Drugs Market

  • 19.1. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anti-Asthmatics And COPD Drugs Market

  • 20.1. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anti-Asthmatics And COPD Drugs Market

  • 21.1. Eastern Europe Anti-Asthmatics And COPD Drugs Market Overview
  • 21.2. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anti-Asthmatics And COPD Drugs Market

  • 22.1. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anti-Asthmatics And COPD Drugs Market

  • 23.1. North America Anti-Asthmatics And COPD Drugs Market Overview
  • 23.2. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anti-Asthmatics And COPD Drugs Market

  • 24.1. USA Anti-Asthmatics And COPD Drugs Market Overview
  • 24.2. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anti-Asthmatics And COPD Drugs Market

  • 25.1. Canada Anti-Asthmatics And COPD Drugs Market Overview
  • 25.2. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anti-Asthmatics And COPD Drugs Market

  • 26.1. South America Anti-Asthmatics And COPD Drugs Market Overview
  • 26.2. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anti-Asthmatics And COPD Drugs Market

  • 27.1. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anti-Asthmatics And COPD Drugs Market

  • 28.1. Middle East Anti-Asthmatics And COPD Drugs Market Overview
  • 28.2. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anti-Asthmatics And COPD Drugs Market

  • 29.1. Africa Anti-Asthmatics And COPD Drugs Market Overview
  • 29.2. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anti-Asthmatics And COPD Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Anti-Asthmatics And COPD Drugs Market Competitive Landscape
  • 30.2. Anti-Asthmatics And COPD Drugs Market Company Profiles
    • 30.2.1. GlaxoSmithKline plc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AstraZeneca plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Boehringer Ingelheim GmbH
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Anti-Asthmatics And COPD Drugs Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Chiesi Farmaceutici S.p.A.
  • 31.3. Teva Pharmaceutical Industries Limited
  • 31.4. Merck & Co. Inc.
  • 31.5. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.6. China National Pharmaceutical Group Co. Ltd. (Sinopharm)
  • 31.7. Shanghai Acebright Pharmaceuticals Group Co. Ltd.
  • 31.8. Jiangsu Hengrui Medicine Co. Ltd
  • 31.9. Hanmi Pharmaceutical
  • 31.10. Cipla Limited
  • 31.11. Aurobindo Pharma Limited
  • 31.12. KYORIN Holdings Inc.
  • 31.13. Nichi-Iko Pharmaceutical Co. Ltd.
  • 31.14. Otsuka Pharmaceutical Co. Ltd.
  • 31.15. Daewoong Pharmaceutical Co. Ltd

32. Global Anti-Asthmatics And COPD Drugs Market Competitive Benchmarking

33. Global Anti-Asthmatics And COPD Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market

35. Anti-Asthmatics And COPD Drugs Market Future Outlook and Potential Analysis

  • 35.1 Anti-Asthmatics And COPD Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Anti-Asthmatics And COPD Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Anti-Asthmatics And COPD Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer